Daniel Warren Seekins MD
HIV/AIDS Medicine
Vice President, Hematology and Cell Therapy, Medical Safety Assessment, Bristol-Myers Squibb
Join to View Full Profile
3401 Princeton PikeMailstop: B2.064Lawrenceville, NJ 08648
Phone+1 609-302-4132
Dr. Seekins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of FloridaFellowship, Infectious Disease, 1989 - 1991
HCA Healthcare/Mercer University School of Medicine/Memorial Health University Medical CenterResidency, Internal Medicine, 1986 - 1989- University of Florida College of MedicineClass of 1986
Certifications & Licensure
FL State Medical License 1989 - 2027
GA State Medical License 1987 - 1997
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors
- A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor Start of enrollment: 2001 Aug 01
Publications & Presentations
PubMed
- 2 citationsThe Antiretroviral Pregnancy Registry: Three decades of prospective monitoring for birth defects.Jessica D Albano, Angela E Scheuerle, D Heather Watts, Karen P Beckerman, Lynne M Mofenson
Pharmacoepidemiology and Drug Safety. 2024-06-01 - 13 citationsOverview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.J. Hey-Hadavi, Daniel Seekins, Melissa Palmer, Denise Coffey, John Caminis
Drug Safety. 2021-03-16 - 21 citationsConsensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chroni...William R. Treem, Melissa Palmer, I. Lonjon-Domanec, Daniel Seekins, Lara Dimick-Santos
Drug Safety. 2021-02-01
Press Mentions
Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical TrialsMarch 16th, 2021
Professional Memberships
- Member
- Member
Industry Relationships
- Group Medical Director, CV/Fibrosis/Immunoscience Medical Safety Assessment Lead, Bristol-Myers Squibb2003 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
